NMT医疗集团今天发表的做出终止MIST II研究决定的声明

NMT announces termination of its MIST II trial of PFO closure for migraine

　　2008，1，23  Shelley Wood报道

　　MA-NMT 医疗集团今天宣布，他们正考虑停止MIST II试验，该试验是在美国进行的旨在评价该公司生产的卵圆孔未闭（PFO）封堵器对伴有先兆的偏头痛患者的作用。根据NMT医疗集团今天发表的做出终止MIST II研究的决定的声明，其中部分原因是由于该试验入选患者存在困难，部分是由于需要将资源集中在PFO封堵治疗中风的NMT研究，尤其与该公司核心课题CLOSURE I试验有关。该声明中称：MIST II研究已经在美国20家医学中心启动，但是通过对1400多名偏头痛患者进行筛选仅有少数患者能满足试验的随机化要求。

　　（阜外心血管病医院　高立建　编译）

　　（来源：www.theheart.org）

 NMT announces termination of its MIST II trial of PFO closure for migraine

January 23, 2008 
Shelley Wood

Boston, MA - NMT Medical announced today that it is halting MIST II, its US-based trial evaluating the use of its patent foramen ovale (PFO)-closure device to treat migraine with aura. According to the statement released by NMT today, the company’s decision to halt MIST II is due in part to difficulties enrolling patients in the trial and in part to the need to channel funding toward NMT’s investigation of PFO closure for stroke, in particular the company’s pivotal CLOSURE I trial. MIST II had been under way at 20 US centers, but out of more than 1400 migraine patients screened for enrollment, "only a handful" actually met requirements for randomization, the statement reads.